Literature DB >> 2939949

Modulation of the immune response to tumors by a novel synthetic compound, N-[4-[(4-fluorophenyl)sulfonyl]phenyl] acetamide (CL 259,763).

B S Wang, V Ruszala-Mallon, R E Wallace, R V Citarella, Y I Lin, F E Durr.   

Abstract

CL 259,763, N-[4-[(4-fluorophenyl)sulfonyl]phenyl] acetamide, is an orally active compound capable of modifying the reactivity of certain lymphoid cell populations affected by the growth of a tumor. The compound augmented the response of lymphocytes from tumor-primed animals to syngeneic tumor cells, resulting in a marked increase in tumor cell destruction. Likewise, it enhanced macrophage inhibitory effects on the growth of tumor cells in vitro. These "activated" macrophages were detectable in peritoneal exudates of treated mice 4 to 12 days after receiving a single oral dose of CL 259,763, with peak activity being demonstrable by day 7. The compound also restored the alloreactivity of lymphocytes from immunodepressed mice bearing the Lieberman plasma cell tumor, possibly by interfering with suppressor cells. Macrophages and lymphocytes from treated mice released significantly more IL-1 and IL-2-like factors in culture than did the control counterparts. Sera from treated mice also possessed more colony stimulating factor than those from normal mice. Immunoadjuvant effects were evident when the compound was administered with an inactivated L1210 leukemia vaccine and it enhanced the effectiveness of cytotoxic chemotherapy when given to mice challenged with P388 murine leukemia. These immunomodulating effects of CL 259,763 may hopefully be exploited in efforts to augment the immune response of the host to a progressively growing tumor.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2939949     DOI: 10.1007/bf00205710

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  18 in total

1.  NEOPLASMS IN THYMECTOMIZED MICE FOLLOWING ROOM INFECTION WITH POLYOMA VIRUS.

Authors:  L W LAW
Journal:  Nature       Date:  1965-02-13       Impact factor: 49.962

2.  Impaired immunologic reactivity and recurrence following cancer surgery.

Authors:  F R Eilber; D L Morton
Journal:  Cancer       Date:  1970-02       Impact factor: 6.860

3.  Follow-up observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma.

Authors:  A C Louie; J G Gallagher; K Sikora; R Levy; S A Rosenberg; T C Merigan
Journal:  Blood       Date:  1981-10       Impact factor: 22.113

4.  Lymphokines, homeostasis, and carcinogenesis.

Authors:  C H Evans
Journal:  J Natl Cancer Inst       Date:  1983-08       Impact factor: 13.506

5.  T helper cells in immune mice amplify the primary anti-tumor cytotoxic response.

Authors:  A S Yu; I D Bernstein
Journal:  J Immunol       Date:  1982-08       Impact factor: 5.422

6.  Immunosuppression in plasmacytoma: induction of suppressor cells.

Authors:  Y Chen; L T Hwang; P Heller
Journal:  Clin Exp Immunol       Date:  1982-01       Impact factor: 4.330

7.  Effects of a cloned cell line with NK activity on bone marrow transplants, tumour development and metastasis in vivo.

Authors:  J F Warner; G Dennert
Journal:  Nature       Date:  1982-11-04       Impact factor: 49.962

8.  Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum.

Authors:  R C Bast; J S Berek; R Obrist; C T Griffiths; R S Berkowitz; N F Hacker; L Parker; L D Lagasse; R C Knapp
Journal:  Cancer Res       Date:  1983-03       Impact factor: 12.701

9.  Myeloma-induced immunosuppression: a multistep mechanism.

Authors:  J A Katzmann
Journal:  J Immunol       Date:  1978-10       Impact factor: 5.422

Review 10.  Utilization of monoclonal antibodies in the treatment of leukemia and lymphoma.

Authors:  J Ritz; S F Schlossman
Journal:  Blood       Date:  1982-01       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.